7th International Immunoglobulin Conference: Interlaken Leadership Awards

Area of Science:

• Neurology
• Immunology
• Therapeutics

Background:

• The Interlaken Leadership Awards (ILAs) support research into immunoglobulin (Ig) therapy, particularly for neurological conditions.
• CSL Behring established the ILAs in 2010 to fund critical research in this area.

Purpose of the Study:

• To present research findings from recipients of the 2011/2012 Interlaken Leadership Awards at the 7th International Immunoglobulin Conference.
• To highlight advancements in the use of intravenous immunoglobulin (IVIg) therapy for various neurological disorders.

Main Methods:

• Multi-center Phase II trial assessing IVIg efficacy in paraneoplastic neurological syndromes (PNS).
• Studies on IVIg treatment in mouse models for neuromyelitis optica (NMO) and Duchenne muscular dystrophy (DMD).
• Phase II clinical trial design for preoperative IVIg in myasthenia gravis (MG) and studies on complex regional pain syndrome (CRPS) pathogenesis and treatment response.

Main Results:

• IVIg therapy shows potential efficacy in treating PNS.
• Improved disease scores observed in a mouse model of NMO following IVIg treatment.
• Enhanced motor function and reduced muscle damage in an mdx mouse model of DMD with IVIg therapy.
• IVIg therapy demonstrated success in a proportion of CRPS patients, with a predictive model developed.

Conclusions:

• IVIg therapy holds significant promise for treating a range of neurological disorders, including PNS, NMO, DMD, MG, and CRPS.
• Ongoing and planned clinical trials are crucial for validating these findings in human patients.
• Further research into the immune-mediated pathogenesis of these conditions may lead to more targeted therapies.